The Gastrointestinal Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted overwhelmingly (11 yes, 1 no) to recommend reintroducing tegaserod maleate (Zelnorm, Sloan Pharma) for the treatment of irritable bowel syndrome with constipation (IBS-C) in women without a history of cardiovascular (CV) ischemic disease and who have no more than one risk factor for CV disease.